Q2 2022 Cue Biopharma Inc Earnings And Business Update Call Transcript
Greetings, and welcome to the Cue Biopharma update call. (Operator Instructions). As a reminder, this conference is being recorded.
I would now like to turn this conference over to Mr. Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you, sir. You may begin.
Okay. Thank you, and good afternoon, everyone. Just to remind you, as we proceed through the presentation, we'll convey which slide we're on, and you can advance the slides directly. We appreciate your time and interest in our update call regarding our ongoing trials of CUE-101 as well as CUE-102, our initial representative drug candidates of the IL-2-based CUE-100 series.
Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our Acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development; and Kerri Millar, our Chief Financial Officer. This conference is being recorded and will be available on our website for the next 30
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
